Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific to $66 from $59 and keeps a Buy rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Enovis named 2024 Top Pick, added to Conviction List at Needham
- TD Cowen ups Boston Scientific target, names a best idea for 2024
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific price target raised to $61 from $58 at Morgan Stanley